Updated physician's guide to the off-label uses of oral isotretinoin

Journal of Clinical and Aesthetic Dermatology

Volumn 7, Issue 4, 2014, Pages 22-34

  Nickle, Steven Brandon ^a   Peterson, Nathan ^b   Peterson, Michael ^c  

^a BROWARD HEALTH MEDICAL CENTER   (United States)

^b Aspen Dermatology Residency Program   (United States)

^c Aspen Dermatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZITHROMYCIN; BEXAROTENE; CISPLATIN; DEFLAZACORT; DOXYCYCLINE; ETRETIN; ETRETINATE; FLUOROURACIL; ISOTRETINOIN; PREDNISONE;

CHEMOPROPHYLAXIS; CONDYLOMA ACUMINATUM; DARIER DISEASE; GRANULOMA ANNULARE; HIGH RISK POPULATION; HUMAN; LEUKOPLAKIA; NON MELANOMA SKIN CANCER; OFF LABEL DRUG USE; PHOTOAGING; PHYSICIAN; PITYRIASIS RUBRA PILARIS; PRACTICE GUIDELINE; PSORIASIS; REVIEW; ROSACEA; SKIN CANCER; SKIN LUPUS ERYTHEMATOSUS; SUPPURATIVE HIDRADENITIS; TOPICAL TREATMENT;

EID: 84899109954     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (175)

1. Lowenstein EB, Lowenstein EJ. Isotretinoin systemic therapy and the shadow cast upon dermatology's downtrodden hero. Clin Dermatol. 2011;29(6):652-661.
2. Akyol M, Ozçelik S. Non-acne dermatologic indications for systemic isotretinoin. Am J Clin Dermatol. 2005;6(3):175-84. (Pubitemid 40994260)
3. Baldwin HE. Systemic therapy for rosacea. Skin Therapy Lett. 2007;12(2):1-5,9. Review.
4. Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical retinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol. 1994;130(3):319-324. (Pubitemid 24107870)
5. Jansen T, Plewig G. Clinical and histological variants of rhinophyma, including nonsurgical treatment modalities. Facial Plast Surg. 1998;14(4):241-53. Review. (Pubitemid 29474183)
6. Erdogan FG, Yurtsever P, Aksoy D, Eskioglu F. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol. 1998;134(7):884-885. (Pubitemid 28350204)
7. Irvine C, Kumar P, Marks R. Isotretinoin in the treatment of rosacea and rhinophyma. In: Marks R, Plewig G, eds. Acne and Related Disorders: Proceedings of an International Symposium. London: Martin Dunitz; 1988:301-305.
8. Schmidt JB, Gebhart W, Raff M, Spona J. 13-cis-retinoic acid in rosacea. Clinical and laboratory findings. Acta Derm Venereol. 1984;64:15-21. (Pubitemid 14179561)
9. Dalziel K, Barton S, Marks R. The effects of isotretinoin on follicular and sebaceous gland differentiation. Br J Dermatol. 1987;117(3):317-323. (Pubitemid 17126008)
10. Jansen T, Plewig G, Kligman AM. Diagnosis and treatment of rosacea fulminans. Dermatology. 1994;188(4):251-254. Review. (Pubitemid 24105477)
11. Bostanci O, Borelli C, Schaller M. Treatment of extrafacial rosacea with low-dose isotretinoin. Acta Derm Venereol. 2010;90(4): 409-410.
12. Hoting E, Paul E, Plewig G. Treatment of rosacea with isotretinoin. Pharm Therap. 1986;25:660-663. (Pubitemid 17210593)
13. Dicken CH. Retinoids: a review. J Am Acad Dermatol. 1984;11:541-552. (Pubitemid 14047261)
14. Mahrle G, Bauermeister-Jasso K, Enderer K. Roaccutan bei Akne und Rosacea [abstract]. Z Hautkr. 1985;60:120-124.
15. Marsden JR, Shuster S, Neugebauer M. Response of rosacea to isotretinoin. Clin Exp Dermatol. 1984;9(5):484-488. (Pubitemid 14037168)
16. Gollnick H, Blume-Peytavi U, Szabó EL, et al. Systemic isotretinoin in the treatment of rosacea - doxycycline- and placebo-controlled, randomized clinical study. J Dtsch Dermatol Ges. 2010;8(7):505-515. Epub 2010 Mar 12.
17. Hofer T. Continuous "microdose" isotretinoin in adult recalcitrant rosacea. Clin Exp Dermatol. 2004;29(2):204-205. (Pubitemid 38367214)
18. Uslu M, Savk E, Karaman G, Sendur N. Rosacea treatment with intermediate-dose isotretinoin: follow-up with erythema and sebum measurements. Acta Derm Venereol. 2012;92(1):73-77.
19. Park H, Del Rosso JQ. Use of oral isotretinoin in the management of rosacea. J Clin Aesthet Dermatol. 2011;4(9):54-61.
20. Plewig G, Jansen T, Kligman AM. Pyoderma faciale. A review and report of 20 additional cases: is it rosacea? Arch Dermatol. 1992;128(12):1611-1617. (Pubitemid 23001178)
21. Rosen T, Unkefer RP. Treatment of pyoderma faciale with isotretinoin in a patient with ulcerative colitis. Cutis. 1999;64(2):107-109.
22. Strauss JS. Rosacea fulminans. J Eur Acad Dermatol Venereol. 2001;15(5):385. (Pubitemid 33040105)
23. Selden S. Pyoderma faciale. J Am Acad Dermatol. 2005;53(6):1104-1105; author reply: 1105-1106.
24. Patterson CR, Wilkinson JD, Lewis FM. Rosacea fulminans confined to the nose. J Eur Acad Dermatol Venereol. 2009;23(9):1101-1102. Epub 2009 Apr 2.
25. Firooz A, Firoozabadi MR, Dowlati Y. Rosacea fulminans (pyoderma faciale): successful treatment of a 3-year-old girl with oral isotretinoin. Int J Dermatol. 2001;40(3):203-205. (Pubitemid 32586283)
26. Pereira TM, Vieira AP, Basto AS. Rosacea with extensive extrafacial lesions. Int J Dermatol. 2008;47(1):52-55.
27. Dupont C. How common is extrafacial rosacea? J Am Acad Dermatol. 1986;14(5 Pt 1):839.
28. Ayres S Jr. Extrafacial rosacea is rare but does exist. J Am Acad Dermatol. 1987;16(2 Pt 1):391-392.
29. Smith KW. Perioral dermatitis with histopathologic features of granulomatous rosacea: successful treatment with isotretinoin. Cutis. 1990;46(5):413-415.
30. Plewig G, Nikolowski J, Wolff HH. Action of isotretinoin in acne rosacea and gram-negative folliculitis [abstract]. J Am Acad Dermatol. 1982;6(4 Pt 2 Suppl):766-785.
31. Dicken CH.Treatment of classic pityriasis rubra pilaris. J Am Acad Dermatol. 1994;31(6):997-999. (Pubitemid 24365041)
32. Allison DS, El-Azhary RA, Calobrisi SD, Dicken CH. Pityriasis rubra pilaris in children. J Am Acad Dermatol. 2002;47(3):386-389.
33. Clayton BD, Jorizzo JL, Hitchcock MG, et al. Adult pityriasis rubra pilaris: a 10-year case series. J Am Acad Dermatol. 1997;36(6 Pt 1):959-964. (Pubitemid 27265910)
34. Goldsmith LA, Weinrich AE, Shupack J. Pityriasis rubra pilaris response to 13-cis-retinoic acid (isotretinoin). J Am Acad Dermatol. 1982;6(4 Pt 2 Suppl):710-715. (Pubitemid 12147434)
35. Dicken CH. Isotretinoin treatment of pityriasis rubra pilaris. J Am Acad Dermatol. 1987;16(2 Pt 1):297-301. (Pubitemid 17013718)
36. Gilgor RS, Chiaramonti A, Goldsmith LA, et al. Evaluation of 13-cis-retinoic acid in lamellar ichthyosis, pityriasis rubra pilaris and Darier's disease. Cutis. 1980;25:380-385. (Pubitemid 10134109)
37. Sehgal VN, Srivastava G, Sardana K. Erythroderma/exfoliative dermatitis: a synopsis. Int J Dermatol. 2004;43(1):39-47. (Pubitemid 38180584)
38. Arechalde A, Saurat JH. Management of psoriasis: the position of retinoid drugs. BioDrugs. 2000;13(5):327-333. (Pubitemid 30399445)
39. Honigsmann H, Wolff K. Isotretinoin-PUVA for psoriasis. Lancet. 1983;1:236. (Pubitemid 13171114)
40. Moy RL, Kingston TP, Lowe NJ. Isotretinoin vs etretinate therapy in generalized pustular and chronic psoriasis. Arch Dermatol. 1985;121(10):1297- 1301. (Pubitemid 15248071)
41. Yamauchi PS, Rizk D, Lowe NJ. Retinoid therapy for psoriasis. Dermatol Clin. 2004;22(4):467-476. (Pubitemid 39140776)
42. Gronhoj Larsen F, Steinkjer B, Jakobsen P, et al. Acitretin is converted to etretinate only during concomitant alcohol intake. Br J Dermatol. 2000;143(6):1164-1169. (Pubitemid 32052750)
43. Al-Shobaili H, Al-Khenaizan S. Childhood generalized pustular psoriasis: successful treatment with isotretinoin. Pediatr Dermatol. 2007;24(5):563-564. (Pubitemid 47631946)
44. Halverstam CP, Lebwohl M. Nonstandard and off-label therapies for psoriasis. Clin Dermatol. 2008;26(5):546-553.
45. Mortazavi H, Khezri S, Hosseini H, et al. A single blind randomized clinical study: the efficacy of isotretinoin plus narrow band ultraviolet B in the treatment of psoriasis vulgaris. Photodermatol Photoimmunol Photomed. 2011;27(3):159-161.
46. Anstey A, Hawk JL. Isotretinoin-PUVA in women with psoriasis. Br J Dermatol. 1997;136(5):798-799.
47. D'Erme AM, Milanesi N, Difonzo EM, et al. Treatment of refractory subacute cutaneous lupus erythematosus with oral isotretinoin: a valid therapeutic option. Dermatol Ther. 2012;25(3):281-282.
48. Vena GA, Coviello C, Angelini G. Use of oral isotretinoin in the treatment of cutaneous lupus erythematosus [abstract]. G Ital Dermatol Venereol. 1989;124:311-315. (Pubitemid 20107858)
49. Shornick JK, Formica N, Parke AL. Isotretinoin for refractory lupus erythematosus. J Am Acad Dermatol. 1991;24:49-52.
50. Richardson TT, Cohen PR. Subacute cutaneous lupus erythematosus: report of a patient who subsequently developed a meningioma and whose skin lesions were treated with isotretinoin. Cutis. 2000;66:183-188.
51. Ruzicka T, Meurer M, Bieber T. Efficiency of acitretin in the treatment of cutaneous lupus erythematosus. Arch Dermatol. 1988;124:897-902.
52. Ruzicka T, Sommerburg C, Goerz G, et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol. 1992;127(5):51.
53. Al-Mutairi N, Rijhwani M, Nour-Eldin O. Hypertrophic lupus erythematosus treated successfully with acitretin as monotherapy. J Dermatol. 2005;32(6):482.
54. Shimizu S, Yasui C, Kawasaki H, Tsuchiya K. Dramatic efficacy of oral aromatic retinoid in long-standing hypertrophic lupus erythematosus. Acta Derm Venereol. 2004;84(6):491.
55. Slade DEM, Powell BW, Mortimer PS. Hidradenitis suppurativa: pathogenesis and management. Br J Plast Surg. 2003;56:451-461. (Pubitemid 37062792)
56. Jansen T, Altmeyer P, Piewig G. Acne inversa (alias hidradenitis suppurativa). J Eur Acad Dermatol Venereol. 2001;15:532-540. (Pubitemid 34044089)
57. Boer J, Van Gemert MJ. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol. 1999;40(1):73-76. (Pubitemid 29051027)
58. Dicken CH, Powell ST, Spear KL. Evaluation of isotretinoin treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1984;11(3): 500-502. (Pubitemid 14068629)
59. Brown CF, Gallup DG, Brown VM. Hidradenitis suppurativa of the anogenital region: response to isotretinoin. Am J Obstet Gynecol. 1988;158(1):12-15. (Pubitemid 18043326)
60. Norris JF, Cunliffe WJ. Failure of treatment of familial widespread hidradenitis suppurativa with isotretinoin. Clin Exp Dermatol. 1986;11(6):579-583. (Pubitemid 17186081)
61. Soria A, Canoui-Poitrine F, Wolkenstein P, et al. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients' outcome assessment. J Am Acad Dermatol. 1999;40(1):73-76.
62. Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer?. Br J Dermatol. 2011;164(1):170-175.
63. Piaserico S, Zattra E, Linder D, Peserico A. Generalized granuloma annulare treated with methylaminolevulinate photodynamic therapy. Dermatology. 2009;218(3):282-284. Epub 2009 Jan 21.
64. Looney M, Smith KM. Isotretinoin in the treatment of granuloma annulare. Ann Pharmacother. 2004;38(3):494-497. Epub 2004 Jan 23.
65. Pasmatzi E, Georgiou S, Monastirli A, Tsambaos D. Temporary remission of disseminated granuloma annulare under oral isotretinoin therapy. Int J Dermatol. 2005;44(2):169-171. (Pubitemid 40305544)
66. Tang WY, Chong LY, Lo KK. Resolution of generalized granuloma annulare with isotretinoin therapy. Int J Dermatol. 1996;35:455-456. (Pubitemid 26196040)
67. Schleicher SM, Milstein HJ, Lim SJM, Stanton CD. Resolution of disseminated granuloma annulare with isotretinoin. Int J Dermatol. 1992;31:371-372.
68. Buendía-Eisman A, Ruiz-Villaverde R, Blasco-Melguizo J, Serrano-Ortega S. Generalized annular granuloma: response to isotretinoin. Int J Dermatol. 2003;42(4):321-322.
69. Sahin MT, Türel-Ermertcan A, Oztürkcan S, Türkdogan P. Generalized granuloma annulare in a patient with type II diabetes mellitus: successful treatment with isotretinoin. J Eur Acad Dermatol Venereol. 2006;20(1):111-114.
70. Baskan EB, Turan A, Tunali S. A case of generalized granuloma annulare with myelodysplastic syndrome: successful treatment with systemic isotretinoin and topical pimecrolimus 1% cream combination. J Eur Acad Dermatol Venereol. 2007;21(5):693-695. (Pubitemid 46916777)
71. Young HS, Coulson IH. Granuloma annulare following waxing induced pseudofolliculitis- resolution with isotretinoin. Clin Exp Dermatol. 2000;25:274-276. (Pubitemid 30670581)
72. Ratnavel RC, Norris PG. Perforating granuloma annulare: response to treatment with isotretinoin. J Am Acad Dermatol. 1995;32:126-127.
73. Adams DC, Hogan DJ. Improvement of chronic generalized granuloma annulare with isotretinoin. Arch Dermatol. 2002;138(11):1518-1519. (Pubitemid 35315752)
74. Pasmatzi E, Kapranos N, Monastirli A, et al. Large benign condyloma acuminatum: successful treatment with isotretinoin and interferon alpha. Acta Derm Venereol. 2012;92(3):249-250.
75. Cardamakis E, Kotoulas IG, Relakis K. Comparative study of systemic interferon alfa-2a plus isotretinoin versus isotretinoin in the treatment of recurrent condyloma acuminatum in men. Urology. 1995;45(5):857-860.
76. Benedetti Panici P, Scambia G, Baiocchi G, et al. Randomized clinical trial comparing systemic interferon with diathermocoagulation in primary multiple and widespread anogenital condyloma. Obstet Gynecol. 1989;74:393.
77. Georgala S, Katoulis AC, Georgala C, et al. Oral isotretinoin in the treatment of recalcitrant condylomata acuminata of the cervix: a randomised placebo controlled trial. Sex Transm Infect. 2004;80(3):216-218. (Pubitemid 38746199)
78. Tsambaos D, Georgiou S, Monastirli A, et al. Treatment of condylomata acuminata with oral isotretinoin. J Urol. 1997;158(5): 1810-1812. (Pubitemid 27433158)
79. Olsen EA, Kelly FF, Vollmer RT, et al. Comparative study of systemic interferon alfa-nl and isotretinoin in the treatment of resistant condylomata acuminata. J Am Acad Dermatol. 1989;20(6):1023-1030. (Pubitemid 19151510)
80. Yildirim M, Inaloz HS, Baysal V, et al. A case of condyloma acuminatum treated successfully with low-dose isotretinoin and interferon. Int J Clin Pract. 2004;58(9):889-891. (Pubitemid 39462212)
81. Cardamakis EK, Kotoulas IG, Dimopoulos DP, et al. Comparative study of systemic interferon alfa-2a with oral isotretinoin and oral isotretinoin alone in the treatment of recurrent condylomata acuminata. Arch Gynecol Obstet. 1996;258(1):35-41. (Pubitemid 26016424)
82. Breen E, Bleday R. Condylomata acuminata (anogential warts). In: Grover S, ed. UpToDate. Waltham, Mass: UpToDate; 2012. http://uptodate.com [Accessed Septemer 12, 2012].
83. Sehgal VN, Srivastava G. Darier's (Darier-White) disease/keratosis follicularis. Int J Dermatol. 2005;44(3):184-192. (Pubitemid 40425660)
84. Del Rosso JQ, Horowitz DC. Treatment of Darier's disease with isotretinoin: report of a case. J Am Osteopath Assoc. 1986;86(10):634-638. (Pubitemid 17168196)
85. Eimer L, Lagodin C, Bonavia P, et al. Darier-White disease treated with oral isotretinoin [abstract]. Arch Argent Pediatr. 2011;109(4):e63-e66.
86. Kim C, Fangman W. Keratosis follicularis (Darier-White disease), with an unusual palmoplantar keratoderma. Dermatol Online J. 2007;13(1):7.
87. Rotunda AM, Cotliar J, Haley JC, Craft N. Unilateral Darier's disease associated with migraine headache responsive to isotretinoin. J Am Acad Dermatol. 2005;52(1):175-176. (Pubitemid 40038969)
88. Dicken CH, Bauer EA, Hazen PG. Isotretinoin treatment of Darier's disease. J Am Acad Dermatol. 1982;6(4 Pt 2 Suppl):721-726. (Pubitemid 12147436)
89. Ling TC, Parkin G, Islam J, et al. What is the cumulative effect of long-term, low-dose isotretinoin on the development of DISH? Br J Dermatol. 2001;144:630-632. (Pubitemid 32232030)
90. Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol. 2002;41(1):41-55. Review. (Pubitemid 34051581)
91. Merino R, Hurlé JM. The molecular basis of retinoid action in tumors. Trends Mol Med. 2003;9(12):509-511. (Pubitemid 38017186)
92. Piattelli A, Carinci F, Iezzi G, et al. Oral lichen planus treated with 13-cis-retinoic acid (isotretinoin): effects on the apoptotic process. Clin Oral Investig. 2007;11(3):283-288. Epub 2007 May 5.
93. Rudin C, Marur S. Chemoprevention in oral dysplasia and head and neck cancer. In: Ross M, ed. UpToDate. Waltham, Mass: UpToDate; 2012. Available at: http://uptodate.com [Accessed Septemer 22,2012].
94. Niles RM. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer. Nutrition. 2000;16(11-12):1084-1089.
95. Lingen MW, Polverini PJ, Bouck NP. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. Cancer Res. 1998;58(23):5551-5558. (Pubitemid 28551144)
96. Weninger W, Rendi M, Mildner M, Tschachler E. Retinoids downregulate vascular endothelial growth factor/vascular permeability factor production by normal human kertinocytes. J Invest Dermatol. 1998; 111(5):907-911. (Pubitemid 28509339)
97. Bhutani T, Koo J. A review of the chemopreventative effects of oral retinoids for internal neoplasms. J Drugs Dermatol. 2011;10(11):1292-1298. Review.
98. Sander CA, Pfeiffer C, Kligman AM, Plewig G. Chemotherapy for disseminated actinic keratoses with 5-fluorouracil and isotretinoin. J Am Acad Dermatol. 1997;36(2 Pt 1):236-238. (Pubitemid 27078918)
99. Dalirsani Z, Farajnia S, Javadzadeh Y, et al. The effects of 5-fluorouracil alone and in combination with 13-cis retinoic acid and vitamin D3 on human oral squamous cell carcinoma lines. J Contemp Dent Pract. 2012;13(3):345-350.
100. Majewski S, Skopinska M, Bollag W, Jablonska S. Combination of isotretinoin and calcitriol for precancerous and cancerous skin lesions. Lancet. 1994;344(8935):1510-1511. (Pubitemid 24351726)
101. Skopinska M, Majewski S, Bolleg W, et al. Calcitriol and isotretinoin combined therapy for precancerous and cancerous skin lesions. J Dermatol Treat. 1997;8:5-10. (Pubitemid 27156777)
102. Hong WK, Endicott J, Itri LM, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med. 1986;315(24): 1501-1505. (Pubitemid 17052146)
103. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med. 1993;328(1):15-20. (Pubitemid 23011466)
104. Scardina GA, Carini F, Maresi E, et al. Evaluation of the clinical and histological effectiveness of isotretinoin in the therapy of oral leukoplakia: ten years of experience: is management still up to date and effective? Methods Find Exp Clin Pharmacol. 2006;28(2): 115-119.
105. Szumilo J, Podlodowska J, Podlodowski W, et al. [Chemoprevention of oral cancer-clinical and experimental studies]. Pol Merkur Lekarski. 2012;32(188):138-142.
106. Duvic M, Lemak NA, Redman JR, et al. Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 1996;35(4):587.
107. Cheeley J, Sahn RE, Delong LK, Parker SR. Acitretin for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol. Epub 2012 Aug 20.
108. Kessler JF, Meyskens FL Jr, Levine N, et al. Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid. Lancet. 1983;1(8338):1345-1347. (Pubitemid 13100195)
109. Neely SM, Mehlmauer M, Feinstein DI. The effect of isotretinoin in six patients with cutaneous T-cell lymphoma. Arch Intern Med. 1987;147(3):529-531. (Pubitemid 17036596)
110. Shin DM, Glisson BS, Khuri FR, et al. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol. 2002;20(2):364-370. (Pubitemid 34072517)
111. Lippman SM, Parkinson DR, Itri LM, et al. 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst. 1992;84(4):235-241.
112. Danopoulou I, Korfitis C, Koliarakis N, Trafalis DT. Rapid improvement of extensive non-melanoma skin cancers with combination of 13-cis-retinoic acid and radiotherapy: report of three cases. J BUON. 2009;14(3):515-517.
113. Martins, R. Systemic treatment of advanced cutaneous squamous and basal cell carcinomas. In: Ross M, ed. UpToDate. Waltham, Mass: UpToDate; 2012. Available at: http://uptodate.com [Accessed September 20, 2012].
114. Campbell RM, DiGiovanna JJ. Skin cancer chemoprevention with systemic retinoids: an adjunct in the management of selected high-risk patients. Dermatol Ther. 2006;19:306-314. (Pubitemid 44470115)
115. Kraemer KH, DiGiovanna JJ, Moshell AN, et al. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med. 1988;318(25):1633-1637.
116. Goldberg LH, Hsu SH, Alcalay J. Effectiveness of isotretinoin in preventing the appearance of basal cell carcinomas in basal cell nevus syndrome. J Am Acad Dermatol. 1989;21(1):144-145. (Pubitemid 19171485)
117. Kraemer KH, DiGiovanna JJ, Peck GL. Chemoprevention of skin cancer in xeroderma pigmentosum. J Dermatol. 1992;19(11):715-718. (Pubitemid 23119632)
118. Saade M, Debahy NE, Houjeily S. Clinical remission of xeroderma pigmentosum-associated squamous cell carcinoma with isotretinoin and chemotherapy: case report. J Chemother. 1999;11(4):313-317. (Pubitemid 29382629)
119. Somos S, Farkas B, Schneider I. Cancer protection in xeroderma pigmentosum variant (XP-V). Anticancer Res. 1999;19(3B):2195-2199. (Pubitemid 29392521)
120. Moshell AN. Prevention of skin cancer in xeroderma pigmetosum with oral Isotretinoin. Cutis. 1989;43:485-487.
121. Levine N, Moon TE, Cartmel B, et al. Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev. 1997;6(11):957-961. (Pubitemid 27481645)
122. Clouser MC, Roe DJ, Foote JA, et al. Dose response of retinol and isotretinoin in the prevention of nonmelanoma skin cancer recurrence. Nutr Cancer. 2010;62(8):1058-66.
123. Bath-Hextall F, Leonardi-Bee J, Somchand N, et al. Interventions for preventing non-melanoma skin cancers in high-risk groups. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005414.
124. Tangrea JA, Edwards BK, Taylor PR, et al. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group. J Natl Cancer Inst. 1992;84(5):328-332.
125. Robinson JK, Salasche SJ. Isotretinoin does not prevent basal cell carcinoma. Arch Dermatol. 1992;128(7):975-976.
126. Kraemer KH, DiGiovanna JJ, Peck GL. Isotretinoin does prevent skin cancer. Arch Dermatol. 1993;129(1):43. (Pubitemid 23029664)
127. Brewster AM, Lee JJ, Clayman GL, et al. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol. 2007;25(15): 1974-1978. (Pubitemid 46972779)
128. Hartman R, Mandal R, Sanchez M, Stein JA. Porokeratosis plantaris, palmaris, et disseminata. Dermatol Online J. 2010;16(11):22.
129. Gutierrez EL, Galarza C, Ramos W, et al. Facial porokeratosis: A series of six patients. Australas J Dermatol. 2010;51(3):191-194.
130. Tsiskarishvili NV, Katsitadze AG, Tsiskarishvili Tsl. Perifolliculitis capitis abscedens et suffodiens (case report)]. Georgian Med News. 2012 Apr;(205):19-23. [abstract].
131. Mihić LL, Tomas D, Situm M, et al. Perifolliculitis capitis abscedens et suffodiens in a caucasian: diagnostic and therapeutic challenge. Acta Dermatovenerol Croat. 2011;19(2):98-102.
132. Koca R, Altinyazar HC, Ozen OI, Tekin NS. Dissecting cellulitis in a white male: response to isotretinoin. Int J Dermatol. 2002;41(8):509-513. (Pubitemid 35023438)
133. Georgala S, Korfitis C, Loannidou D, et al. Dissecting cellulites of the scalp treated with rifampicin and isotretinoin: case reports. Cutis. 2008:82(3):195-198.
134. Khaled A, Zeglaoui F, Zoghlami A, et al. Dissecting cellulitis of the scalp: response to isotretinoin. J Eur Acad Dermatol Venereol. 2007;21(10):1430-1431. (Pubitemid 350020165)
135. Bjellerup M, Wallengren J. Familial perifolliculitis capitis absedens et sufffodiens in two brothers successfully treated with Isotretinoin. J Am Acad Dermatol. 1990;23:752-753. (Pubitemid 20336410)
136. Bachynsky T, Antony-shyn OM, Ross JB. Dissecting folliculitis of scalp-a case report of combined treatment using tissue expansion, radical excision, and isotretinoin. J Dermatol Surg Oncol. 1992;18:877-880.
137. Helfman RJ. Grover's disease treated with isotretinoin. Report of four cases. J Am Acad Dermatol. 1985;12(6):981-984. (Pubitemid 15058963)
138. Mancuso A, Cohen EH. Transient acantholytic dermatosis treated with isotretinoin. J Am Osteopath Assoc. 1990;90(2):179-182. (Pubitemid 20085831)
139. Mutizwa MM, Berk DR. Dichotomous long-term response to isotretinoin in two patients with fordyce spots. Pediatr Dermatol. Epub 2012 Apr 4.
140. Monk BE. Fordyce spots responding to isotretinoin therapy. Br J Dermatol. 1993;129(3):355. (Pubitemid 23284026)
141. Grimalt R, Ferrando J, Mascaro JM. Premature familial sebaceous hyperplasia: successful response to oral isotretinoin in three patients. J Am Acad Dermatol. 1997;37(6):996-998. (Pubitemid 28016635)
142. McDonald SK, Goh MS, Chong AH. Successful treatment of cyclosporine induced sebaceous hyperplasia with oral isotretinoin in two renal transplant recipients. Australas J Dermatol. 2011;52(3):227-230.
143. Yu C, Shahsavari M, Stevens G, Liskanich R, Horowitz D. Isotretinoin as monotherapy for sebaceous hyperplasia. J Drugs Dermatol. 2010;9(6):699-701.
144. Kaufmann R, Vranes M, Landes E. [Diffuse (presenile) hyperplasia of the sebaceous glands, a new entity? Successful treatment with 13-cis-retinoic acid]. Hautarzt. 1987;38(1):31-35.
145. Burton CS, Sawchuk WS. Premature sebaceous gland hyperplasia: successful treatment with isotretinoin. J Am Acad Dermatol. 1985;12(1 Pt 2):182-184. (Pubitemid 15192924)
146. Grekin RC, Ellis CN. Isotretinoin for the treatment of sebaceous hyperplasia. Cutis. 1984;34(1):90-92. (Pubitemid 14086093)
147. Saleh HA, Lloyd KM, Fatteh S. Kyrle's disease. Effectively treated with isotretinoin. J Fla Med Assoc. 1993;80(6):395-397. (Pubitemid 23238156)
148. Serdar ZA, Altunay IK, Yasar SP, et al. Generalized papular and sclerodermoid eruption:scleromyxedema. Indian J Dermatol Venereol Leprol. 2010;76(5):592.
149. Milam CP, Cohen LE, Fenske NA, Ling NS. Scleromyxedema: therapeutic response to isotretinoin in three patients. J Am Acad Dermatol. 1988;19:469-477.
150. Hisler BM, Sovaj LB, Hashimoto K. Improvement of scleromyxedema associated with isotretinoin therapy. J Am Acad Dermatol. 1991;24:854-857.
151. Lominska-Lasota K, Rosen-Uzelac G, Reichl W, Bauer R. [Scleromyxedema therapy with isotretinoin]. Z Hautkr. 1988;63(2):137-138,141.
152. Layton AM, Cunliffe WJ. A case of ulerythema ophryogenes responding to isotretinoin. Br J Dermatol. 1993;129(5):645-646. (Pubitemid 23336474)
153. Berbis P, Jancovici E, Lebreuil G, et al. Eosinophilic pustular folliculitis (Ofuji's disease): efficacy of isotretinoin. Dermatologica. 1989;179(4):214-216. (Pubitemid 20020177)
154. Fekete GL, Fekete JE. Steatocystoma multiplex generalisata partially suppurativa-case report. Acta Dermatovenerol Croat. 2010;18(2):114-119.
155. Apaydin R, Bilen N, Bayramgürler D, et al. Steatocystoma multiplex suppurativum: oral isotretinoin treatment combined with cryotherapy. Australas J Dermatol. 2000;41(2):98-100. (Pubitemid 30304003)
156. Moritz DL, Silverman RA. Steatocystoma multiplex treated with isotretinoin: a delayed response. Cutis. 1988;42(5):437-439. (Pubitemid 19005564)
157. Rosen BL, Brodkin RH. Isotretinoin in the treatment of steatocystoma multiplex: a possible adverse reaction. Cutis. 1986;37(2):115,120.
158. Yang H, Ahmed I, Mathew V, Schroeter AL. Diffuse dermal angiomatosis of the breast. Arch Dermatol. 2006;142(3):343-347.
159. McLaughlin ER, Morris R, Weiss SW, Arbiser JL. Diffuse dermal angiomatosis of the breast: response toisotretinoin. J Am Acad Dermatol. 2001;45(3):462-465. (Pubitemid 32800509)
160. Beauregard S. [Cutis verticis gyrata and pachydermoperiostosis. Several cases in a same family. Initial results of the treatment of pachyderma with isotretinoin]. Ann Dermatol Venereol. 1994;121(2):134-137.
161. Park YK, Kim HJ, Chung KY. Pachydermoperiostosis: trial with isotretinoin. Yonsei Med J. 1988;29(2):204-207.
162. Apalla Z, Karakatsanis G, Papageorgiou M, et al. A case of atrophoderma vermiculatum responding to systemic isotretinoin. J Dermatol Case Rep. 2009;3(4):62-63.
163. Richard G, Harth W. [Keratosis follicularis spinulosa decalvans. Therapy with isotretinoin and etretinate in the inflammatory stage]. Hautarzt. 1993;44(8):529-534.
164. Graefe T, Wollina U, Schulz H, Burgdorf W. Muir-Torre syndrome-treatment with isotretinoin and interferon alpha-2a can prevent tumor development. Dermatology. 2000;200(4):331-333. (Pubitemid 30451584)
165. Marcusson JA, Bjarnason B, Ros AM. Isotretinoin for sebaceous skin lesions in Muir-Torre syndrome: a case report. Acta Derm Venereol. 1998;78(6):479-480. (Pubitemid 28505975)
166. Spielvogel RL, DeVillez RL, Roberts LC. Oral isotretinoin therapy for familial Muir-Torre syndrome. J Am Acad Dermatol. 1985;12(3):475-480. (Pubitemid 15144632)
167. Gerber PA, Meller S, Eames T, et al. Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients. Eur J Med Res. 2012;17(1):4.
168. Rabello-Fonseca R, Azulay D, Luiz R, et al. Oral isotretinoin in photoaging: clinical and histopathological evidence of efficacy of an off-label indication. J Eur Acad Dermatol Venereol [serial online]. 2009;23(2):115-123.
169. Smith LA, Cohen DE. Successful long-term use of oral isotretinoin for management of morbihan disease: a case series report and review of the literature. Arch of Dermatol. 2012;148(12):1395-1398.
170. Maddin S, Lauharanta J, Agache P, et al. Isotretinoin improves the appearance of photodamaged skin: results of a 36-week, multicenter, double-blind, placebo controlled trial. J Am Acad Dermatol. 2000;42:56-63. (Pubitemid 30470320)
171. Grove GL, Grove MJ, Thorne EG, Lufrano L. Topical tretinoin for photodamaged skin. J Am Acad Dermatol. 1986;15:836-840.
172. Kalil C, Fachinello FZ, Lamb F, Comunello L. Use of oral isotretinoin in photoaging therapy. Skinmed. 2008;7(1):10-14.
173. Hernandes-Perez E, Khawaja HA, Alvarez TY. Oral isotretinoin as part of treatment of cutaneous aging. Dermatol Surg. 2000;26:649-652. (Pubitemid 30470628)
174. Ellis CN, Krach KJ. Uses and complications of isotretinoin therapy. J Am Acad Dermatol. 2001;45:S150-S157. (Pubitemid 33032594)
175. Bagatin E, Parada M, Miot H, et al. A randomized and controlled trial about the use of oral isotretinoin for photoaging. Int J Dermatol. [serial online]. February 2010;49(2):207-214.